- Home
- GNFT vs RNAC Comparison
GNFT vs RNAC Comparison
Compare GNFT & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- RNAC
- Stock Information
- Founded
- GNFT 1999
- RNAC 2007
- Country
- GNFT France
- RNAC United States
- Employees
- GNFT N/A
- RNAC N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- RNAC Health Care
- Exchange
- GNFT Nasdaq
- RNAC Nasdaq
- Market Cap
- GNFT 214.5M
- RNAC 242.4M
- IPO Year
- GNFT 2019
- RNAC 2016
- Fundamental
- Price
- GNFT $3.93
- RNAC $9.92
- Analyst Decision
- GNFT Strong Buy
- RNAC Strong Buy
- Analyst Count
- GNFT 1
- RNAC 6
- Target Price
- GNFT $13.00
- RNAC $41.25
- AVG Volume (30 Days)
- GNFT 3.3K
- RNAC 65.3K
- Earning Date
- GNFT 04-24-2025
- RNAC 08-07-2025
- Dividend Yield
- GNFT N/A
- RNAC N/A
- EPS Growth
- GNFT N/A
- RNAC N/A
- EPS
- GNFT 0.03
- RNAC N/A
- Revenue
- GNFT $73,187,701.00
- RNAC $34,173,000.00
- Revenue This Year
- GNFT $15.98
- RNAC N/A
- Revenue Next Year
- GNFT N/A
- RNAC N/A
- P/E Ratio
- GNFT $124.79
- RNAC N/A
- Revenue Growth
- GNFT 105.01
- RNAC 31.91
- 52 Week Low
- GNFT $2.55
- RNAC $8.46
- 52 Week High
- GNFT $6.42
- RNAC $29.65
- Technical
- Relative Strength Index (RSI)
- GNFT 42.09
- RNAC 47.60
- Support Level
- GNFT $4.03
- RNAC $9.72
- Resistance Level
- GNFT $4.61
- RNAC $10.56
- Average True Range (ATR)
- GNFT 0.12
- RNAC 0.67
- MACD
- GNFT -0.05
- RNAC 0.07
- Stochastic Oscillator
- GNFT 0.00
- RNAC 42.91
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.